Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ene.14368 http://scihub22266oqcxt.onion/10.1111/ene.14368 32478936!7300656!32478936     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32478936.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Eur+J+Neurol 2020 ; 27 (9): 1751-1753 Nephropedia Template TP {{tp|p=32478936|t=2020. SARS-CoV-2 and Guillain-Barre syndrome: AIDP variant with a favourable outcome |pdf=|usr=}}{{32478936}} gab.com Text SARS-CoV-2 and Guillain-Barre syndrome: AIDP variant with a favourable outcome JO: Eur J Neurol http://www.kidney.de/pget.php?&tw=1&pmid=32478936 #FOAvip BACKGROUND AND PURPOSE: The spectrum of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2), includes different neurologic manifestations of the central and peripheral nervous system. METHODS: From March through April 2020, in two university hospitals located in western Switzerland, we examined three patients with Guillain-Barre syndrome (GBS) following SARS-CoV-2. RESULTS: These cases were characterized by a primary demyelinating electrophysiological pattern (Acute inflammatory demyelinating polyneuropathy or AIDP) and a less severe disease course compared to recently published case series. Clinical improvement was observed in all patients at week five. One patient was discharged from hospital after full recovery with persistence of minor neurological signs (areflexia). Two of the three patients remained hospitalized: one was able to walk and the other could stand up with assistance. CONCLUSIONS: We report three cases of typical GBS (AIDP) occurring after SARS-CoV-2 infection and presenting with a favourable clinical course. Given the interval between COVID-19-related symptoms and neurological manifestations (mean of 15 days) we postulate a secondary immune-mediated mechanism rather than direct viral damage. Twit Text FOAVip SARS-CoV-2 and Guillain-Barre syndrome: AIDP variant with a favourable outcome ????Eur J Neurol http://www.kidney.de/pget.php?&tw=1&pmid=32478936 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32478936 #FOAvip English Wikipedia <ref>{{Cite pmid|32478936}}</ref> SARS-CoV-2 and Guillain-Barre syndrome: AIDP variant with a favourable outcome #MMPMID32478936 Lascano AM; Epiney JB; Coen M; Serratrice J; Bernard-Valnet R; Lalive PH; Kuntzer T; Hubers A Eur J Neurol 2020[Sep]; 27 (9): 1751-1753 PMID32478936show ga BACKGROUND AND PURPOSE: The spectrum of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2), includes different neurologic manifestations of the central and peripheral nervous system. METHODS: From March through April 2020, in two university hospitals located in western Switzerland, we examined three patients with Guillain-Barre syndrome (GBS) following SARS-CoV-2. RESULTS: These cases were characterized by a primary demyelinating electrophysiological pattern (Acute inflammatory demyelinating polyneuropathy or AIDP) and a less severe disease course compared to recently published case series. Clinical improvement was observed in all patients at week five. One patient was discharged from hospital after full recovery with persistence of minor neurological signs (areflexia). Two of the three patients remained hospitalized: one was able to walk and the other could stand up with assistance. CONCLUSIONS: We report three cases of typical GBS (AIDP) occurring after SARS-CoV-2 infection and presenting with a favourable clinical course. Given the interval between COVID-19-related symptoms and neurological manifestations (mean of 15 days) we postulate a secondary immune-mediated mechanism rather than direct viral damage. |COVID-19/*complications[MESH] |Disease Progression[MESH] |Female[MESH] |Guillain-Barre Syndrome/drug therapy/*etiology/physiopathology[MESH] |Humans[MESH] |Immunoglobulins, Intravenous/therapeutic use[MESH] |Middle Aged[MESH] |Neural Conduction/*physiology[MESH] |Switzerland[MESH]SARS-CoV-2 and Guillain-Barre syndrome: AIDP variant with a favourable(epmc).pdf DeepDyve Pubget Overpricing